Sodium dichromate

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Type of information:

migrated information: read-across based on grouping of substances (category approach)

Adequacy of study:

supporting study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Review of non-standard literature studies

Data source

Reference

Reference Type:

other: Criteria Document

Title:

Criteria Document for Hexavalent Chromium

Author:

Cross HJ et al

Year:

1997

Bibliographic source:

Institute of Occupational Health, UK

Materials and methods

Principles of method if other than guideline:

Reviews of various published, non-standard mechanistic studies.

GLP compliance:

no

Remarks:

Published studies

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

Potassium dichromate

EC Number:

231-906-6

EC Name:

Potassium dichromate

Cas Number:

7778-50-9

Molecular formula:

Cr2H2O7.2K

IUPAC Name:

potassium dichromate

Constituent 2

Reference substance name:

Potassium chromate

EC Number:

232-140-5

EC Name:

Potassium chromate

Cas Number:

7789-00-6

Molecular formula:

CrH2O4.2K

IUPAC Name:

Potassium chromate

Constituent 3

Reference substance name:

Sodium chromate

EC Number:

231-889-5

EC Name:

Sodium chromate

Cas Number:

7775-11-3

Molecular formula:

CrH2O4.2Na

IUPAC Name:

disodium dioxido(dioxo)chromium

Details on test material:

The IOH review summarises the results of a number of studies performed with potassium dichromate, potassium chromate or sodium chromate following subcutaneous injection or intraperitoneal administration at dose levels of 2 mg Cr (VI) / kg.

Test animals

Species:

rat

Sex:

not specified

Administration / exposure

Route of administration:

other: Intraperitoneal or subcutaneous

Doses:

2 mg/kg bw Cr (VI)

No. of animals per sex per dose:

Not reported

Results and discussion

Any other information on results incl. tables

Effects indicative of renal toxicity (altered urinary protein or enzyme levels, histopathology of the proximal tubular epithelium) were reported in these studies.

Applicant's summary and conclusion

Conclusions:

The acute administration of low doses of Cr (VI) compounds by parenteral (subcutaneous or intraperitoneal) injection to rats was found to cause kidney toxicity.

Executive summary:

Acute administration of low doses of Cr (VI) compounds by parenteral (subcutaneous or intraperitoneal) injection to rats was found to cause kidney toxicity. These findings are therefore consistent with the known effects of Cr (VI) toxicity and do not raise any additional concerns. The relatively low dose levels resulting in toxicity in these studies compared to those seen following oral and dermal dosing reflects the relatively poor bioavailability of Cr (VI) compounds by these routes of exposure.